Search Results - gregory+tawa

3 Results Sort By:
Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration
Summary: The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations. Description of Technology: Inherited Retinal Degenerations (IRD), such as Leber...
Published: 12/20/2024   |   Inventor(s): Anand Swaroop, Yu Holly Chen, Samantha Papal, Anupam Mondal, Manju Swaroop, Wei Zheng, Gregory Tawa, Wenwei Huang, Zhiji Luo
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Ear, Nose, & Throat, Collaboration Sought > Licensing
Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic...
Published: 10/28/2024   |   Inventor(s): Jian-kang Jiang, Khalida Shamim, Philip Sanderson, Wei Zheng, Xiuli Huang, Gregory Tawa, Asaf Alimardanov, Arthur Lee, Junfeng Huang, Wenwei Huang
Keywords(s): ALK2, BMP, INHIBITING, Inhibitors, Methods, Novel, SIGNALING, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Endocrinology, Application > Therapeutics, Application > Research Materials
Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties
This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and...
Published: 10/28/2024   |   Inventor(s): Scott Hoyt, Patrick Sutter, Chris Finocchio, Daniel Starczynowski, Gregory Tawa, Craig Thomas
Keywords(s): 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX
Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology